Nautilus Biotechnology (NASDAQ:NAUT) reported third-quarter revenue of $200,000 as it continued its transition toward ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

Vir Biotechnology (VIR) has signed a collaboration and license agreement with Gilead focused on three PRO-XTEN dual-masked ...

Nautilus Biotechnology, Inc. reported its financial results for the third quarter ended September 30, 2026. Revenue was $0.2 million for the third quarter of 2026, primarily driven by grant revenue ...

The Treasury Department’s proposed restrictions on U.S. investment in Chinese biopharma collide with Beijing’s new export ...

The UC Santa Cruz Genomics Institute partnered with Santa Cruz Works to host a rooftop mixer in late October 2025 that fostered new connections among researchers, local entrepreneurs, investors, and ...

Industrial biotechnology has the potential to save the planet up to 2.5 billion tons of CO2 emissions per year and support building a sustainable future, a WWF report found. Industrial biotechnology ...

Nautilus Biotechnology (NAUT) is scheduled to announce Q3 earnings results on Tuesday, October 27th, before market open. The consensus EPS Estimate is -$0.14 and the consensus Revenue Estimate is ...

Nautilus Biotechnology, Inc. is currently listed on NASDAQ under NAUT. One share of NAUT stock can currently be purchased for approximately $2.94. Is Nautilus Biotechnology, Inc. listed on the NASDAQ ...

Stem cell biotechnology is a field of biotechnology that develops tools and therapeutics through modification and engineering of stem cells. Stem cell biotechnology is important in regenerative ...